Table 1.

Patient demographics and baseline characteristics

Prior on-demand group* (n = 13)Switch group (n = 10)
Age, y   
 Mean (SD) 38.0 (17.6) 43.9 (21.8) 
 Median (range) 30.0 (20-67) 34.0 (18-77) 
Sex, n (%)   
 Male 5 (38.5) 7 (70.0) 
 Female 8 (61.5) 3 (30.0) 
Body mass index, kg/m2   
 Mean (SD) 23.3 (3.1) 23.3 (3.5) 
 Median (range) 23.6 (17.8-29.3) 23.7 (17.7-28.6) 
VWD type, n (%)   
 Type 1 2 (15.4) 1 (10.0) 
 Type 2A 1 (10.0) 
 Type 2B 1 (7.7) 
 Type 3 10 (76.9) 8 (80.0) 
VWF:RCo, IU/dL   
 Mean (SD) 5.6 (10.7) 0.8 (2.6) 
 Median (range) 0 (0-27.8) 0 (0-8.3) 
FVIII:C, IU/dL   
 Mean (SD) 25.9 (40.6) 10.3 (12.5) 
 Median (range) 3.0 (2-111) 3.5 (1-40) 
Prior on-demand group* (n = 13)Switch group (n = 10)
Age, y   
 Mean (SD) 38.0 (17.6) 43.9 (21.8) 
 Median (range) 30.0 (20-67) 34.0 (18-77) 
Sex, n (%)   
 Male 5 (38.5) 7 (70.0) 
 Female 8 (61.5) 3 (30.0) 
Body mass index, kg/m2   
 Mean (SD) 23.3 (3.1) 23.3 (3.5) 
 Median (range) 23.6 (17.8-29.3) 23.7 (17.7-28.6) 
VWD type, n (%)   
 Type 1 2 (15.4) 1 (10.0) 
 Type 2A 1 (10.0) 
 Type 2B 1 (7.7) 
 Type 3 10 (76.9) 8 (80.0) 
VWF:RCo, IU/dL   
 Mean (SD) 5.6 (10.7) 0.8 (2.6) 
 Median (range) 0 (0-27.8) 0 (0-8.3) 
FVIII:C, IU/dL   
 Mean (SD) 25.9 (40.6) 10.3 (12.5) 
 Median (range) 3.0 (2-111) 3.5 (1-40) 

FVIII:C, factor VIII clotting (activity).

*

Patients who were treated on-demand with any VWF during the 12-month period before enrolling in this study.

Patients who were treated prophylactically with a pdVWF for ≥12 months before enrolling in this study.

or Create an Account

Close Modal
Close Modal